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Understanding pathways that promote HIV-1 broadly neutralizing antibody (bnAb) induction is crucial to advance bnAb-
based vaccines. We recently demarcated host, viral, and disease parameters associated with bnAb development in a large 
HIV-1 cohort screen. By establishing comprehensive antibody signatures based on IgG1, IgG2, and IgG3 activity to 13 HIV-1 
antigens in 4,281 individuals in the same cohort, we now show that the same four parameters that are significantly linked 
with neutralization breadth, namely viral load, infection length, viral diversity, and ethnicity, also strongly influence HIV-1–
binding antibody responses. However, the effects proved selective, shaping binding antibody responses in an antigen and IgG 
subclass–dependent manner. IgG response landscapes in bnAb inducers indicated a differentially regulated, IgG1-driven HIV-1 
antigen response, and IgG1 binding of the BG505 SOS IP trimer proved the best predictor of HIV-1 neutralization breadth 
in plasma. Our findings emphasize the need to unravel immune modulators that underlie the differentially regulated IgG 
response in bnAb inducers to guide vaccine development.
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Introduction
Broadly neutralizing antibodies (bnAbs) to HIV-1 are defined by 
their superior activity against genetically diverse HIV-1 strains, 
referred to as neutralization breadth. Elite bnAbs that pair 
breadth with extraordinary potency are currently developed 
as lead components of vaccines and therapeutics (Burton and 
Hangartner, 2016; Caskey et al., 2016; Escolano et al., 2017; Pegu 
et al., 2017). bnAb responses are rare (10–25%) in natural infec-
tion, with highly potent elite bnAbs only detected in an estimated 
1% of HIV-1 infections (Burton and Hangartner, 2016; Moore and 
Williamson, 2016; Rusert et al., 2016), and no vaccine thus far has 
succeeded in inducing bnAb activity (Burton and Hangartner, 
2016; Escolano et al., 2017). Key elements that restrict and pro-
mote bnAb induction in natural HIV-1 infection thus need to be 
unraveled and exploited to overcome barriers in vaccine devel-
opment. This includes the search for distinct HIV-1 Envelope 
(Env) variants that prime and mature bnAb responses (Wu et 
al., 2010; Sanders et al., 2015; Jardine et al., 2016; Stamatatos et 
al., 2017; Ward and Wilson, 2017) and a quest to define host, viral, 
and disease factors that stimulate bnAb development (Haynes 
et al., 2016; Landais et al., 2016; Moore and Williamson, 2016; 
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Rusert et al., 2016; Borrow and Moody, 2017). Based on cohort 
studies and in-depth analyses of bnAb and virus coevolution in 
individual patients, various parameters have been implicated as 
drivers of bnAb induction. These include exposure to high loads 
of viral antigen over several years of infection and a high viral 
diversity as a result of virus evolution or superinfection (Sather 
et al., 2009; Cortez et al., 2012; Doria-Rose et al., 2014; Goo et al., 
2014; Hraber et al., 2014; Bhiman et al., 2015; Landais et al., 2016; 
Rusert et al., 2016). In addition, a range of immune parameters 
including peripheral CD4 cell levels, distinct regulatory CD4 T 
cell subsets (Moody et al., 2016; Borrow and Moody, 2017), soluble 
CXCL13 (Havenar-Daughton et al., 2016; Dugast et al., 2017), and 
specific HLA variants (Landais et al., 2016) have been implicated 
in bnAb evolution.
To decipher factors that promote bnAb activity and their indi-
vidual influence we recently conducted a systematic survey of 
bnAb activity in 4,484 chronically HIV-1–infected individuals 
(Rusert et al., 2016). This population-wide screen, which we now 
refer to as the Swiss 4.5K Screen, identified 239 patients as bnAb 
inducers and discerned four main parameters significantly asso-
ciated with bnAb development: infection length, viral load, viral 
diversity, and black ethnicity. Here, building on the Swiss 4.5K 
Screen, we generate a landscape of HIV-1 Env and Gag binding 
antibody responses in the same patient cohort to define immune 
regulatory principles that underlie the link between the iden-
tified factors and bnAb evolution. In particular, we seek to (1) 
delineate parameters that steer HIV-binding antibody responses, 
(2) define if and how these parameters intersect with factors 
that steer bnAb development, (3) investigate shifts in the HIV 
antibody response landscape linked with the development of 
neutralization breadth, and (4) identify HIV-binding antibody 
signatures that define neutralization breadth.
Results
Systematic survey of factors that steer IgG subclass responses 
to HIV-1 Env and Gag antigens
A key aspect of bnAb evolution that awaits resolution is whether 
bnAbs are unique in the dependence on cofactors or whether 
these factors also drive other HIV-1–specific antibody responses. 
Building on the Swiss 4.5K Screen (Rusert et al., 2016), we per-
formed a comprehensive survey of plasma IgG activity in 4,281 
asymptomatic, viremic, chronic HIV-1–infected individuals 
(Fig. 1, A–G) to 13 HIV-1 antigens (Fig. 1 H), including Gag anti-
gens p17 and p24 and several Env antigens comprising the closed, 
native-like BG505 trimer, open Env conformations (gp120 [JR-
FL] and gp140 [BG505]), and distinct epitope regions (V3 loop, 
CD4-binding site [CD4bs], membrane proximal external region 
[MPER], and gp41ΔMPER; Fig.  1  I and Tables S1 and S2). The 
obtained serology data (Fig. 1 I) were then used to probe for inter-
relations of HIV-binding antibody activity with viral, host, and 
disease determinants and neutralization breadth (Fig. 1 A).
HIV-1 IgG subclass responses can differ dependent on the HIV 
antigen type, disease progression, and immunization regimen 
(Klasse et al., 1990; Lal et al., 1991; Thomas et al., 1996; Binley et 
al., 1997; Ngo-Giang-Huong et al., 2001; Voltersvik et al., 2003; 
Martinez et al., 2005; Banerjee et al., 2010; French et al., 2013; 
Lai et al., 2014; Yates et al., 2014; Chung et al., 2015; Ackerman et 
al., 2017). Here, we established a landscape of HIV-1 IgG subclass 
responses in chronic HIV-1 infection across Gag and Env antigens, 
focusing on IgG1, IgG2, and IgG3, as HIV-1 IgG4 responses are 
known to be low (Broliden et al., 1989; Banerjee et al., 2010). In line 
with the known dominance of IgG1 in HIV-1 infection (Broliden et 
al., 1989; Binley et al., 1997; Banerjee et al., 2010), IgG1 responses 
showed the highest reactivity across all antigens, followed by IgG3 
and IgG2 responses (Fig. 1 I). Using the collected binding data, we 
used multivariable linear regression models to assess how individ-
ual factors influence HIV-1 IgG responses. Results from univariable 
analysis are additionally provided to highlight which effects are 
most affected by other variables. We assessed eight parameters, for 
which we had complete datasets for 3,159 individuals: two patient 
characteristics (gender and ethnicity) and six viral and disease 
parameters (viral load and CD4 level at the time point of sampling, 
pol diversity, infection length, transmission mode, and HIV-1 pol 
subtype; Figs. 2 and 3; and Tables S2 and S3).
Black ethnicity is linked with higher IgG1 
responses to HIV-1 Env
A main driving factor of bnAb elicitation identified in the Swiss 
4.5K Screen was black ethnicity (Rusert et al., 2016). Here we 
show that black ethnicity is significantly linked with elevated 
IgG1 Gag and several IgG1 Env responses, but not with IgG2 Env 
and only marginally with IgG3 Env (Fig. 2, A and B), suggesting 
the manifestation of an immune stimulatory environment that 
specifically promotes IgG1 responses.
White individuals in our cohort are mostly infected with 
HIV-1 subtype B, whereas non-B subtypes are predominantly 
represented within other ethnicities (Schoeni-Affolter et al., 
2010; Rieder et al., 2011; Rusert et al., 2016; Table S2). Multivari-
able analysis revealed that the effect of ethnicity on HIV-binding 
antibodies was independent of the infecting subtype (Fig. 2, A 
and B). We did not attempt a direct assessment of the influence 
of the infecting subtype on binding antibody responses, as it is 
expected that in the binding assay, antibodies preferentially rec-
ognize antigens that are derived from the same subtype and that 
recognition of antigens from other subtypes can vary (Fig. 2, A 
and C). To formally exclude an influence of the analyte subtype in 
subsequent analyses, we examined, in addition to the full dataset, 
also the subcohort of white individuals infected with subtype B 
(white/B subcohort; n = 2,762) as indicated throughout our study 
(Fig. 3 and Table S2).
Differential influence of viral load, diversity, and 
infection length
Untreated HIV-1 infection is characterized by an inverse relation-
ship of CD4 levels and viral loads (Mellors et al., 1997). Although 
this was also apparent in our cohort (Fig. 1, E and F), multivariable 
analysis paired with the large sample size enabled a dissection of 
individual influences of CD4 cell and viral load levels. Viral load 
portrayed a dichotomy by showing a highly significant, negative 
effect on IgG1 p17, IgG1 p24, and IgG3 gp41ΔMPER responses, 
contrasted by a positive association with IgG1 gp41ΔMPER and 
IgG2 gp120 responses, in particular the IgG2 BG505 trimer and 
BG505 gp140 reactivity (Fig. 2 A and Fig. 3, A and B). A differential 
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regulation of Gag and Env antibody responses has been noted for 
long. In particular, low anti-Gag IgG responses have been sug-
gested to be linked with disease progression, possibly reflecting 
the waning CD4 cell counts at later disease stages and potentially 
unveiling a higher dependence of Gag responses on CD4 help 
(Broliden et al., 1989; Klasse et al., 1990; Lal et al., 1991; Thomas 
et al., 1996; Binley et al., 1997; Ngo-Giang-Huong et al., 2001; 
Voltersvik et al., 2003; Trkola et al., 2004; Martinez et al., 2005; 
Tomaras and Haynes, 2009; Banerjee et al., 2010; French et al., 
2010, 2013; Yates et al., 2014; Chung et al., 2015; Ackerman et al., 
2016). Results from multivariable testing in our cohort, however, 
suggested otherwise, revealing that CD4 levels by themselves have 
a marginal effect on shaping HIV-binding antibody responses in 
asymptomatic chronic infection (Fig. 2 A and Fig. 3, A and C). Two 
observations were particularly noteworthy. First, IgG1 p17, IgG1 
p24, and IgG3 gp41ΔMPER responses all exhibited a strong nega-
tive dependency on viral load, but were not significantly affected 
by CD4 levels when controlled for influence of other factors in the 
multivariable analysis. Second, the IgG1 responses to MPER and 
gp41ΔMPER were positively linked with lower CD4 counts.
Viral diversity, defined per pol sequence ambiguity, is strongly 
positively associated with bnAb development in our cohort (Rusert 
et al., 2016). Intriguingly, diversity also positively influenced gp120 
responses (irrespective of the antigen subtype or its monomeric 
or trimeric state), but not Gag, MPER, or gp41ΔMPER responses 
(Fig. 2 A and Fig. 3, A and D). The effect was largely restricted to IgG1, 
but also notable for some IgG2 and IgG3 Env responses. Thus, in line 
with the higher genetic variability of gp120, antibody responses 
to gp120 appear to improve upon exposure to a higher viral diver-
sity, whereas the responses to the genetically more conserved 
Gag, MPER, and gp41ΔMPER antigens remain largely unaffected. 
Remarkably, diversity had the strongest effect on BG505 trimer 
binding both in the full cohort and the white/B subcohort.
Infection length, which is also strongly positively linked with 
bnAb development in our cohort (Rusert et al., 2016), predomi-
nantly influenced IgG1 responses across Gag and Env antigens, 
Figure 1. Systematic survey of IgG subclass responses to HIV-1 Env and Gag antigens. (A) Experimental study design. Red arrows indicate aspects 
examined in the current study. (B and C) Distribution of ethnicities (B) and HIV-1 subtypes (C) in the cohort. (D) Relative size of the white/B subcohort. (E and 
F) Scatterplot of log10 viral load and CD4 cell count for the full cohort (E) and the white/B subcohort (F). A red linear regression line and the Spearman and 
Pearson correlation coefficients are shown. (G) Distribution of log10 viral load in females and males in the full cohort (pMann-Whitney = 1.1e-20). (H) Overview of 
13 HIV-1 antigens selected for IgG response monitoring. (I) Summary of measured IgG-binding antibody response (MFI raw data; Luminex binding assay; single 
measurements) in 4,281 chronic HIV-1–infected individuals. Relative binding activities (Table S1) derived from these MFI raw data were used for further analysis.
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whereas no or low influence was observed for IgG2 and IgG3 
responses, respectively (Fig. 2 A and Fig. 3, A and E).
Patient demographic influences on the HIV-1 IgG response
We observed interesting patient demographic effects among 
females and intravenous drug users (IDUs). We previously 
noted that females developed neutralization breadth slightly 
less frequently than males in our cohort (Table S7 in Rusert et 
al., 2016). Here, we show that females exhibited higher p17 and 
p24 IgG1 responses (Fig. 2 A; Fig. 3 A; and Table S3). Both these 
responses were strongly negatively affected by viral load (Fig. 2 A 
and Fig. 3, A and B). However, although females are known to 
Figure 2. Influence of host, viral and disease 
parameters on binding antibody responses 
across all ethnicities. (A) The influence of the 
virus load, CD4 count, viral diversity, length of 
untreated HIV-1 infection, transmission route, 
gender, ethnicity, and HIV-1 subtype on binding 
antibody responses to each tested HIV-1 antigen 
was determined by univariable (inner squares) 
and multivariable (outer squares) linear regres-
sion for all three IgG subclasses (n = 3,159). Only 
significant associations (P < 0.05) are colored, and 
the Bonferroni-corrected significance threshold 
(P = 0.00012) is shown in the color map. Color 
intensity represents the significance level of pos-
itive (blue) and negative (red) associations. See 
Table S3 for detailed regression results. (B and C) 
Impact of the indicated parameter on the relative 
IgG1 (black), IgG2 (green), and IgG3 (blue) binding 
activity, based on the same multivariable linear 
regression analysis as in A. Error bars depict the 
95% confidence intervals. Nonsignificant associ-
ations are marked by n.s. and are shown in lighter 
color shades. * highlights significant associations 
when using a Bonferroni correction for multiple 
testing. (B) Influence of black compared with 
white individuals. (C) Non–B-infected compared 
with B-infected individuals.
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Figure 3. Influence of host, viral and disease parameters on binding antibody responses in the white/B subcohort. (A) The influence of the virus load, 
CD4 count, viral diversity, length of untreated HIV-1 infection, gender, and transmission route on binding antibody responses was determined by univariable 
(inner squares) and multivariable (outer squares) linear regression for each IgG subclass and each HIV-1 antigen (n = 2,122). Only significant associations 
(P < 0.05) are colored, and the Bonferroni-corrected significance threshold (P = 0.00016) is shown in the color map. Color intensity represents the significance 
level of positive (blue) and negative (red) associations. See Table S3 for detailed regression results. (B–E) Impact of the indicated parameter on the relative IgG1 
(black), IgG2 (green), and IgG3 (blue) binding activity, based on the same multivariable linear regression analysis as in A. Error bars depict the 95% confidence 
intervals. Nonsignificant associations are marked by n.s. and are shown in lighter color shades. * highlights significant associations when using a Bonferroni 
correction for multiple testing. (B) Impact of viral load per unit increase in log10 viral copy numbers per milliliter of blood. (C) Impact of CD4 cell count per 
200 cells/µl decrease in CD4 cell count. (D) Impact of viral diversity per 0.01 increase in pol diversity. (E) Impact of infection length per 1,000 d increase in 
length of untreated HIV-1 infection.
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have lower viral loads than males (Sterling et al., 2001; Hagen 
and Altfeld, 2016), which was also the case in our study (Fig. 1 G), 
multivariable testing confirmed that the higher IgG1 p17 and p24 
responses in females occurred independently of the viral load. 
Quite remarkable was the difference in IgG2 responses. Females 
developed less IgG2-binding antibodies across all 13 tested HIV-1 
antigens (Fig. 2 A and Fig. 3 A), strongly suggesting specific influ-
ences on IgG2 class-switch pathways.
IDUs mounted significantly stronger IgG1 binding to various 
HIV-1 antigens in line with a previously suggested, differential 
IgG activity of IDUs (Bongertz et al., 1999), but showed no differ-
ence in IgG2 and IgG3 responses (Fig. 2 A and Fig. 3 A). Although 
triggers of the enhanced IgG1 response are likely different in 
IDUs, the observed pattern is largely reminiscent of what we 
observed in black individuals. Intriguingly, IDUs in our cohort 
develop neutralization breadth slightly more frequently (Table 
S7 in Rusert et al., 2016), which, in conjunction with the obser-
vations made for black individuals, suggests the existence of 
immune regulatory mechanisms that promote a dominant IgG1 
pathway linked with neutralization breadth.
IgG1-driven HIV antibody response landscape is linked with 
the development of neutralization breadth
The predominance of IgG1-binding antibodies in individuals with 
black ethnicity and IDUs prompted us to investigate the influence 
of cofactors on the pattern of IgG subclass responses. Comparing 
the relative binding activities between IgG subclasses (IgG1-IgG2, 
IgG1-IgG3, and IgG2-IgG3) in the full cohort (Fig. 4, A–C) and the 
white/subtype B subcohort (Fig. 4, D–F) highlighted a predom-
inant IgG1 response to several Env antigens that is linked with 
neutralization breadth (Fig. 4, G–I). Of note, high IgG1 activity 
to the BG505 trimer was a strong indicator of neutralization 
breadth as was a high IgG3 MPER activity.
To investigate global shifts in antibody response landscapes 
that are linked with neutralization breadth, we compared cor-
relation networks of binding responses of nonneutralizers and 
potent neutralizers (individuals with previously defined broad 
and elite neutralization activity [Rusert et al., 2016]). To enable 
an unbiased evaluation, we restricted the analysis to the white/B 
subgroup and therein to individuals with chronic HIV-1 infec-
tion (3–10 yr untreated infection) to ensure comparable infec-
tion length in neutralizers and nonneutralizers as detailed in 
the methods section. The accordingly defined subcohorts (Fig. 5, 
A–C; and Table S2) of nonneutralizers (n = 1,341; Fig. 6 A) and 
potent neutralizers (broad and elite activity; n = 95; Fig.  6  B) 
were then subjected to a correlation network analysis (Fig. 5 D). 
Potent neutralizers showed significant shifts in correlations for 
the majority of antigens both within the same IgG subclass and 
across subclasses (Fig.  6  C). Focusing on in-between subclass 
associations of responses to each antigen (Fig. 5 E), we detected 
significantly lower associations between IgG1/IgG2 and IgG1/
IgG3 responses, but not between IgG2/IgG3 in potent neutraliz-
ers (Fig. 6 D), which was driven by an increase in IgG1 responses 
(Fig. 4). Of note, MPER responses constituted the only exception 
to the IgG1 driven shift in neutralizers.
Importantly, we show that this IgG1-driven antibody response 
landscape develops with disease progression increasing from 
early to late HIV infection (Fig. 7), lending further support that the 
widely observed late development of bnAbs (after three or more 
years of untreated infection) is tied to immune regulatory changes.
Besides the observed global shifts in IgG subclass associations 
between nonneutralizers and neutralizers (Fig. 4), the correla-
tions among IgG1 responses also markedly differed (Fig. 6). Non-
neutralizers displayed a strong correlation between IgG1 activ-
ity to the BG505 trimer and several open Env antigens (BG505 
gp140, V3 BG505, and JR-FL gp120) that was considerably lower 
in neutralizers, highlighting a qualitative and quantitative shift 
in the IgG1 anti-Env responses between the two groups.
Immune signatures linked with neutralization breadth
To distinguish HIV-binding antibody signatures that define neu-
tralization breadth, we compared HIV IgG reactivity in patient 
groups with elite, broad, and cross neutralization activity to 
individuals with no or low neutralization activity (Rusert et 
al., 2016). To minimize potential confounders, we focused this 
analysis on the white/B subcohort. Importantly, all relevant find-
ings remained valid in the full cohort (Table S4). A first visual 
comparison of the relative IgG reactivity for each antigen and 
IgG subclass indicated that high reactivity to certain antigens 
is more frequent among individuals with cross, broad, and elite 
neutralization activity (Fig. 8 A). Intriguingly, the most evident 
difference between bnAb developers and nonneutralizers was 
in the activity against the BG505 trimer consistent with the 
concept that trimer binding is a prerequisite for neutralization 
(Sattentau and Moore, 1995; Yasmeen et al., 2014; Sanders et al., 
2015; Burton and Hangartner, 2016).
Quantification of the predictive strength of antigen binding 
on HIV-1 neutralization by the area under curve (AUC) of the 
receiver-operating characteristic (ROC) disclosed a wide range 
of HIV IgG reactivity with predictive power toward identifying 
neutralization breadth (Fig. 8, B and C; and Table S4). IgG1 bind-
ing to the BG505 trimer proved to be the best single indicator of 
neutralizing activity with AUC values of up to 0.849, followed by 
IgG2 BG505 trimer and JR-FL gp120 (AUCs of up to 0.749 and 0.713, 
respectively). Solely based on IgG1 BG505 trimer binding activity 
50.9% of elite, 44.0% of broad, and 27.6% of cross neutralizers in 
the white/B subcohort could be identified at a false positive rate 
of 10% (Fig. 8 C). Accepting 30% false positives, these numbers 
increased to 89.5%, 78.1%, and 57.8%, respectively. To define HIV 
immune signatures that maximize neutralization breadth pre-
dictions, we next established logistic-regression based models on 
multiple binding activities. Starting with the IgG1 BG505 trimer, 
the model was expanded in a greedy fashion by iteratively adding 
the predictor with the best predictive power (Fig. 8 D). Interest-
ingly, the predictive power saturated quickly, and the four best 
choices for the second and third variable yielded similar predictive 
values (Fig. 8, E–G). Across elite, broad, and cross neutralization, 
a common three-variable immune signature for neutralization 
prediction emerged, characterized by high reactivity with a 
closed Env conformation (IgG1 and IgG2 BG505 trimer), but lower 
reactivity with an open Env conformation (IgG1 BG505 gp140), 
validating the recognized importance of trimer binding for neu-
tralization activity (Sattentau and Moore, 1995; Yasmeen et al., 
2014; Sanders et al., 2015; Burton and Hangartner, 2016). Notably, 
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several IgG2 responses were among the best predictors in these 
multiparameter prediction signatures (Fig. 8, D–G), supporting a 
role of IgG2 responses as surrogate markers also in neutralization 
breadth development (Lal et al., 1991; Ngo-Giang-Huong et al., 
2001; Martinez et al., 2005; French et al., 2010, 2013).
Immune signatures linked with neutralization specificity
To probe for immune signatures that are linked with certain 
bnAb specificities, we investigated binding antibody patterns 
in 105 bnAb plasma samples, for which epitope specificity was 
previously predicted by neutralization fingerprint analysis 
(Fig.  9 and Table S5; Rusert et al., 2016). For two bnAb types, 
CD4bs and MPER, specific antigens (RSC3/RSC3Δ and MPER 
peptides, respectively) were included in our screen and thus 
allowed us to quantify the impact of epitope-specific binding in 
predicting bnAb types. Many antibodies targeting the CD4bs, 
including the bnAb VRC01, strongly react with RSC3 but not 
RSC3Δ, which lacks a crucial isoleucine at position 371 (Wu et 
Figure 4. Comparison of relative binding activities between IgG subclasses. (A–I) Analysis of the full cohort (n = 3,159; A–C and G–I) and the white/B sub-
cohort (n = 2,122; D–I) with complete data on the included host, viral, and disease parameters. The influence of the virus load, CD4 count, viral diversity, length 
of untreated HIV-1 infection, transmission route, gender, neutralization breadth (at least cross neutralization), ethnicity, and HIV-1 subtype on the differences 
in binding antibody responses to each tested HIV-1 antigen was determined by univariable (inner squares) and multivariable (outer squares) linear regression 
for all three pairs of IgG subclasses. Only significant associations (P < 0.05) are colored, and the Bonferroni-corrected significance threshold (P = 0.00012) is 
shown in the color map. The color intensity represents the significance level. (G–I) Difference in neutralizers and nonneutralizers in differential IgG subclass 
(ΔIgG) binding activity, based on the same multivariable linear regression analysis as in A–F. Error bars depict the 95% confidence intervals. Nonsignificant 
associations are marked by n.s. and are shown in lighter color shades.
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al., 2010). Accordingly, the neutralization fingerprint similarity 
to CD4bs bnAbs in our cohort was linked with enhanced IgG1 
binding to RSC3 and a higher ratio of IgG1 RSC3 to RSC3Δ bind-
ing (Fig. 9, A and C), confirming the validity of the neutraliza-
tion fingerprint and highlighting the presence of VRC01-like 
bnAbs. Intriguingly, the neutralization fingerprint similarity to 
MPER bnAbs was significantly associated with both IgG1 and 
IgG3 MPER binding with IgG1 yielding an even stronger effect 
(Fig. 9, A and D).
To further explore the association of IgG1 and IgG3 MPER 
binding responses with MPER targeting bnAb activity, we 
selected four markers, the two strongest positive markers of 
breadth (IgG1 and IgG2 BG505 trimer, which does not include the 
MPER domain) and the strongest MPER bnAb predictors (IgG1 
and IgG3 MPER 2/4) and used this data to generate two-dimen-
sional maps of the full cohort using the dimensionality reduction 
algorithm t-SNE (Fig. 10 A) and stratified according to the plasma 
neutralization activity (Fig. 10, B–D). Visualization of the IgG1 
and IgG3 MPER single- and double-positive population (Fig. 10 E) 
side by side with plasmas with predicted MPER bnAb activity 
(Fig. 10 F; Rusert et al., 2016) in the same t-SNE plots revealed 
that 18 of 19 predicted MPER bnAbs fell into regions with MPER 
responses that were either dominant IgG3, dominant IgG1, or 
had a high IgG1 and IgG3 MPER reactivity, suggesting that MPER 
bnAb evolution should not be restricted to IgG3.
Discussion
The identification of immune regulatory pathways that are 
critical for bnAb elicitation by vaccines ultimately depends on 
decoding immune profiles linked with bnAb development in nat-
ural infection. Here, we applied a systems serology approach to 
retrieve HIV-1 antibody–binding signatures in 4,281 participants 
of the Swiss 4.5K Screen to define markers of bnAb induction. 
Exploring factors that steer HIV-1–binding antibody reactivity, 
we found that the same four parameters that are significantly 
linked with bnAb breadth in our cohort (Rusert et al., 2016), 
namely viral load, infection length, viral diversity, and ethnicity, 
Figure 5. Distribution of untreated infection length and set-up of correlation network analyses. (A) Patient selection for the antibody response land-
scape analyses in Figs. 6 and 7. (B) Distribution of untreated infection length in the white/B subcohort. Colors distinguish early (n = 519) and late (n = 2,243) 
chronic infection and indicate subcohorts of early and late infection analyzed in Fig. 7. All samples with an untreated infection of >15 yr are grouped together 
(n = 96). (C) Distribution of untreated infection length in the white/B subcohort in individuals with 3- to 10-yr untreated infection and with no or weak neutral-
ization activity (left; n = 1,341) or potent (broad or elite) neutralization activity (right; n = 95). The two distributions do not differ significantly (pMann-Whitney = 0.70). 
(D) Example of the correlation network analyses shown in Figs. 6 (A–C) and 7 (A–C). The relative binding activities to each antigen and each IgG subclass were 
compared with all other relative binding activities, as exemplified for IgG1 BG505 trimer binding. (E) Example of the correlation network analysis as conducted 
in Figs. 6 D and 7 D. Only the correlations between the IgG1 and IgG2 responses of the same antigen were investigated. Correlations for IgG1/IgG3 and IgG2/
IgG3 responses were conducted the same way.
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also strongly influence HIV-1–binding antibody responses. Yet, 
their effect proved selective, shaping antibody responses in an 
antigen- and IgG subclass–dependent manner. This results in 
complex antibody immune signatures that are driven by combi-
nations of parameters.
Based on the known antigenicity of the BG505 trimer, bnAbs 
are expected to preferentially bind this probe (Yasmeen et al., 
2014). Interestingly, among the factors that prominently influence 
bnAb breadth, diversity, and infection length, but not viral load, 
were strongly positively linked with BG505 trimer IgG1 reactiv-
ity, suggesting that antigen quantity may not be the rate-limiting 
factor in the development of trimer-reactive antibodies. Infec-
tion length and viral diversity influenced the majority of IgG1 
responses to gp120 antigens, but not MPER antigens. Likewise, 
there was no independent effect of infection length on IgG1 activ-
ity to the CD4bs specific probe RSC3. In sum, these results suggest 
that dependent on the desired antibody specificity vaccine strate-
gies may need to simulate a different set of parameters.
This also includes the role of CD4 cells. Low CD4 levels have 
been suggested to foster potent bnAb development in some 
cohorts monitored for bnAb activity (Gray et al., 2011; Landais et 
al., 2016), but not in others (Piantadosi et al., 2009; Doria-Rose 
et al., 2010; Rusert et al., 2016). As CD4 levels and viral load are 
inversely correlated, and viral load strongly influences bnAb 
activity, assessing the independent contribution of CD4 levels to 
antibody evolution is critical. We previously showed that CD4 lev-
els alone have no significant effect on the development of potent 
bnAb responses, but that, in agreement with earlier studies, less 
Figure 6. Differential landscape of HIV-1 IgG responses in broad neutralizers. (A and B) Pairwise Spearman correlation analysis of the relative binding 
activities to the 13 HIV-1 antigens within and between subclass IgG1 (dark green), IgG2 (light green), and IgG3 (gray) in white subtype B–infected patients with 
late chronic (3- to 10-yr untreated) infection. Correlations with a magnitude >0.15 are depicted in blue (positive associations) and red (negative associations). The 
strength of Spearman correlation is signified by color intensity for correlations with magnitudes from 0.15 to 0.5 and additionally by line width for magnitudes 
>0.5. (A) Patients with no or low neutralizing activity (n = 1,673). (B) Patients with broad or elite neutralizing activity (n = 143). (C) Significant differences (pshuffle 
< 0.05; 10,000 random reshuffles) in pairwise Spearman correlations between broad neutralizers (as in B) and nonneutralizers (as in A) are shown. Green and 
orange shaded lines denote correlations that increase or decrease among broad neutralizers, respectively. The significance level of differences is depicted by 
color intensity and additionally by line width for differences that remain significant after correction for multiple testing (Benjamini-Hochberg correction with a 
false discovery rate of 10%; pshuffle ≤ 0.0016). (D) The distribution of all pairwise between IgG subclass correlations of individual antigens (Fig. 5 E) is shown for 
the nonneutralizers (light violet) and potent (broad or elite) neutralizers (dark violet). Significant p-values from a paired Wilcoxon test are shown.
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potent, cross-neutralizing activity is more frequently linked with 
lower CD4 levels (Rusert et al., 2016). Analyzing the same cohort 
of patients, we show now that CD4 levels have no strong impact on 
shaping gp120-binding responses. In contrast, the gp41 response, 
in particular MPER reactivity, was strongly inversely linked with 
CD4 levels (Figs. 2 and 3). MPER bnAbs are frequently autoreac-
tive and it has been suggested that their evolution may benefit 
from a CD4-impaired environment with reduced tolerance con-
trol mechanisms (Haynes et al., 2005; Chen et al., 2013; Zhang et 
al., 2016; Borrow and Moody, 2017; Kelsoe and Haynes, 2017). The 
pronounced effect of low CD4 levels on gp41/MPER binding anti-
bodies but not on potent bnAb development in our cohort sug-
gests that employment of tolerance-modulating interventions to 
boost bnAb activity needs to be carefully balanced. Based on our 
results, the majority of bnAb types are unlikely to benefit sub-
stantially from a CD4 low environment but this could remain a 
possibility in the context of MPER vaccination regimens.
Females in our cohort developed slightly less neutralization 
breadth (Rusert et al., 2016). We discovered intriguing differ-
ences in the IgG reactivity pattern of females with elevated IgG1 
p17 and p24 responses and a generally decreased IgG2 response. 
This may support a scenario of higher expression of X chromo-
some–linked regulators of the immune response (Fish, 2008; 
Hagen and Altfeld, 2016). The diminished IgG2 binding anti-
bodies across all 13 tested HIV-1 antigens suggest specific influ-
ences on IgG2 class-switch pathways. Of note, IFN-γ has been 
implicated in the development of IgG2 responses (Finkelman et 
al., 1988; Kawano et al., 1994; Vazquez et al., 2015). Lower IFN-γ 
levels in HIV-1–infected females, as recently reported (Yong et 
al., 2016), could thus potentially contribute to the reduced IgG2 
response in females.
A key finding of our study is that IgG subclass responses are 
differentially influenced, leading to distinctive antibody response 
landscapes among neutralizers and nonneutralizers. Particularly 
Figure 7. Correlations of antibody binding responses in early and late chronic infection. (A and B) Pairwise Spearman correlation analysis of the relative 
binding activities to the 13 HIV-1 antigens within and between subclass IgG1 (dark green), IgG2 (light green), and IgG3 (gray) in white subtype B infected patients 
with early chronic (1–3 yr untreated infection; n = 519; A) and late chronic (>3 yr untreated infection; n = 2,243; B) infection. Correlations with a magnitude >0.15 
are depicted in blue (positive associations) and red (negative associations). The strength of Spearman correlation is signified by color intensity for correlations 
with magnitudes from 0.15 to 0.5 and by the strongest color intensity and line width for magnitudes >0.5. (C) Significant differences (pshuffle < 0.05; 10,000 
random reshuffles) in pairwise Spearman correlations between early chronic (as in A) and late chronic (as in B) patients are shown. Green and orange shaded 
lines denote correlations that increase or decrease among late chronic patients, respectively. The significance level of differences is depicted by color intensity 
and by line width for differences that remain significant after correction for multiple testing (Benjamini-Hochberg correction with a false discovery rate of 10%; 
pshuffle ≤ 0.0148). (D) The distribution of all pairwise “between IgG subclass” correlations of individual antigens (Fig. 5 E) is shown for the early chronic (green) 
and the late chronic (violet) patients. Significant p-values from a paired Wilcoxon test are shown.
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Figure 8. HIV-1–binding antibody responses predict bnAb activity. Analysis of white/B subcohort (n = 2,762). (A) Frequency comparison of antigen 
reactivity in patient groups with no or weak- (n = 2,155; light gray), cross- (n = 453; dark gray), broad- (n = 123; black), and elite- (n = 31; red) neutralizing 
activity (Table S2). For each antigen and each IgG subclass, plasma samples were distributed into ten groups based on their relative binding activity, and the 
distribution of neutralizers and nonneutralizers across these groups is depicted. (B and C) Relative binding activities were used in logistic regression models 
to predict whether a plasma with known elite- (red), at least broad- (broad and elite activity: black) or at least cross- (cross, broad, and elite activity: dark gray) 
neutralizing activity was part of the respective group. The AUC of the ROC using fivefold cross validation and 100 repetitions was used to measure predictive 
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notable is the shift to IgG1 over IgG2 and IgG3 responses in neu-
tralizers (Fig.  4). IgG1 is known to generally dominate in HIV 
infection (Broliden et al., 1989; Binley et al., 1997; Tomaras and 
Haynes, 2009; Banerjee et al., 2010). Antibody class switching 
to the four human IgG subclasses occurs through differential 
temporal pathways that are steered by various cytokines and 
epigenetic factors (Stavnezer, 1996; Zan and Casali, 2015; Horns 
et al., 2016). Elevated IgG1 levels may therefore result from con-
ditions that favor subclass switching to IgG1 (Horns et al., 2016), 
increased frequencies of IgG1 specific cells, and/or elevate levels 
of IgG1 secretion (Knox et al., 2017). Of note, the IgG1 response to 
BG505 trimer correlated more strongly with the IgG1 response to 
open Env constructs that reveal the V3 loop (V3 peptides, JR-FL 
gp120, and BG505 gp140) in nonneutralizers than in neutralizers 
(Fig. 6, A–C). Reactivity with open Env constructs was generally 
high in our cohort (Fig. 1 I), but it was not a specific trait of non-
neutralizers (Fig. 8, A and B), suggesting that a qualitative and 
quantitative shift to IgG1 BG505 trimer reactivity in broad and 
elite neutralizers appears to be a distinguishing factor, rather 
than a higher reactivity with open Env in nonneutralizers.
The fact that both black ethnicity and IDU status were sig-
nificantly linked with elevated HIV-specific IgG1-binding activ-
ity and neutralization breadth is highly intriguing and suggests 
that IgG1 driven environments may be triggered by different fac-
tors. Mechanistically, it will be important to define in forthcom-
ing studies whether the shift toward IgG1 responses is a result of 
higher frequencies of IgG1 B cells and/or elevated antibody secre-
tion and to determine the underlying causes to aid incorporation 
of relevant immune modulatory strategies in vaccine regimens.
Although our results generally advocate for a stimulation of 
an IgG1 environment to foster gp120-directed binding and neu-
tralizing responses, demands on the vaccine regimen may differ 
depending on the desired correlates of protection. For example, 
induction of nonneutralizing, antibody-dependent cell-mediate 
cytotoxicity–inducing anti-gp120 IgG3 responses, which were 
considered critical in the outcome of the RV144 trial (Kim et al., 
2015), may depend on other parameters and require differential 
tailored vaccination regimen.
IgG3 responses have also been implicated in the induction of 
MPER bnAbs. Most MPER bnAbs isolated to date are IgG3 (Muster 
et al., 1993; Stiegler et al., 2001; Huang et al., 2012). In support of 
the importance of IgG3 for MPER antibody development, neutral-
izers exhibited higher IgG3 than IgG1 MPER-binding responses 
(Fig.  4). We nevertheless also observed strong links with IgG1 
MPER responses lending support to an alternative scenario, where 
MPER bnAbs may originate in linked IgG3–IgG1 switch pathways, 
suggesting that IgG1 MPER bnAbs should likewise exist.
The comprehensive binding antibody analysis we conducted 
allowed us to explore two further principle questions: Which 
binding antibody responses are best suited to (1) predict bnAb 
activity (Fig. 8) and (2) define bnAb specificity (Fig. 9)? BG505 
trimer reactivity proved the best predictor of neutralization 
breadth. Remarkably, additional parameters added to the pre-
diction signature did only marginally improve the predictive 
capacity (Fig. 8, D–G). Of note, the MPER epitope is not included 
in the soluble BG505 trimer probe; yet, despite the prevalence of 
MPER bnAb inducers in our cohort (19 of 82 bnAb inducers with 
defined specificity (Rusert et al., 2016), MPER binding reactivity 
did not significantly add to the bnAb prediction signature. Our 
data thus strongly suggests that bnAb activity (irrespective of the 
type of bnAb elicited) develops in patients that mount a poly-
clonal trimer-reactive response and that thus reactivity with the 
native trimer, as in our study exemplified by the BG505-SOS IP 
trimer, demarcates a wide spectrum of bnAb activities. We do not 
expect this to be a unique feature of the BG505-SOS IP trimer, but 
rather a feature shared by all antigens that resemble the intact 
trimer. It will be interesting to explore in forthcoming studies the 
differential properties of intact trimer immunogens in demar-
cating neutralization activity to explore ex vivo their potential 
in eliciting desired responses upon vaccination. Although BG505 
trimer reactivity potently indicated breadth in our study, it was 
not a distinctive predictor of bnAb epitope specificity, which was 
best predicted by epitope-specific binding probes such as RSC3 
for CD4bs bnAb activity and MPER peptide reactivity for MPER 
bnAb responses.
In sum, the IgG1-driven landscape of HIV specific responses in 
potent neutralizers we identify here unveils the need of creating 
a specific immune regulatory environment for the development 
of neutralization breadth. Deciphering the basis of these regu-
latory shifts will be important to determine the triggers of this 
bnAb-favoring environment in forthcoming HIV pathogenicity 
studies and vaccine trials and to explore how this environment 
can be induced and maintained in healthy individuals to make 
bnAb-based vaccines possible.
Materials and Methods
Study populations and ethics information
The current study encompassed 4,281 plasma samples from 
viremic, HIV-1–infected individuals previously included in a 
population-wide screen for HIV-1 neutralization breadth, now 
termed the Swiss 4.5K Screen (Rusert et al., 2016). A detailed 
description of sample/patient selection and study design of the 
Swiss 4.5K Screen has been described previously (Rusert et al., 
strength. (B) Comparison of the predictive strength (shades of blue based on AUC values) of all single binding antibody responses. (C) ROC curve using IgG1 
BG505 trimer binding as predictor. Dashed lines indicate the respective true positive rates of cross, broad, and elite neutralization at fixed false positive rates 
of 0.1 and 0.3. The black dotted line y = x indicates the expected performance of a random prediction. (D) Best multivariable prediction model for cross, broad, 
and elite neutralization. The best model with a certain number of variables (up to three) is learned in a greedy fashion and depicted. (+) indicates antibody-bind-
ing responses with a positive parameter in the model (high binding responses are predictive of neutralization breadth). (−) indicates negative parameters 
(low-binding responses are predictive of neutralization breadth). (E–G) At each step, the four best choices are shown from top (best) to bottom (fourth best). 
The respective AUC values and a representation of the impact of each binding activity on the respective model are also depicted. Antibody binding responses 
indicated in blue have a positive parameter in the model; red denotes a negative parameter. (E) Best prediction for cross neutralization. (F) Best prediction for 
broad neutralization. (G) Best prediction for elite neutralization. See Table S4 for AUC values and comparable findings for the full cohort.
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2016). The current study was restricted to 4,281 of the 4,484 
included in the Swiss 4.5K Screen (Rusert et al., 2016) based on 
sample availability. All analyzed plasma samples were derived 
from specimen stored in the biobanks of the Swiss HIV Cohort 
Study (SHCS) and the Zurich Primary HIV Infection Study 
(ZPHI). The SHCS is a prospective, nationwide, longitudinal, 
Figure 9. HIV-1–binding antibody responses associated with specific bnAb types. (A and B) Definition of binding patterns that predict bnAb types. The 
association of two variables, the log10 IgG binding activities (single measurements; A), and the infecting subtype (B vs. non-B) on various bnAb specificities (B) 
was determined by multivariable linear regression, using the Spearman neutralization fingerprint similarity with bnAb clusters of the top neutralizing plasma 
samples (n = 105) as defined in Rusert et al. (2016) as a marker of bnAb specificity. Significant associations (P < 0.05) are colored, with positive and negative 
associations indicated in blue and red, respectively. The color intensity represents the significance level. (C and D) Magnitude and significance of associations 
between the IgG response to CD4bs antigens and CD4bs bnAb activity (C) and MPER antigens and MPER bnAb specificity (D), based on the same multivariable 
linear regression analysis as in A and B. Error bars depict the 95% confidence intervals. Nonsignificant associations (P > 0.05) are marked by n.s.
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noninterventional, observational, clinic-based cohort with semi-
annual visits and blood collections, enrolling all HIV-infected 
adults living in Switzerland (Schoeni-Affolter et al., 2010). The 
SHCS, founded in 1988, is highly representative of the HIV epi-
demiology in Switzerland as it includes an estimated 53% of all 
HIV cases diagnosed in Switzerland since the onset of the epi-
demic, 72% of all patients receiving antiretroviral therapy in 
Switzerland, and 69% of the nationwide registered AIDS cases 
(Schoeni-Affolter et al., 2010; Yang et al., 2015). The SHCS is 
registered under the Swiss National Science longitudinal plat-
form. Detailed information on the study is openly available on 
http:// www .shcs .ch.
The ZPHI is an ongoing, observational, nonrandomized, 
single center cohort founded in 2002 that specifically enrolls 
patients with documented acute or recent primary HIV-1 
infection (http:// www .clinicaltrials .gov; ID NCT00537966; 
Rieder et al., 2011).
The SHCS and the ZPHI have been approved by the ethics com-
mittee of the participating institutions (Kantonale Ethikkom-
mission Bern, Ethikkommission des Kantons St. Gallen, Comite 
Departemental d’Ethique des Specialites Medicales et de Medi-
cine Communataire et de Premier Recours, Kantonale Ethikkom-
mission Zürich, Repubblica e Cantone Ticino - Comitato Ethico 
Cantonale, and Commission Cantonale d'Étique de la Recherche 
sur l'Être Humain, Ethikkommission Beider Basel for the SHCS, 
and Kantonale Ethikkommission Zürich for the ZPHI) and writ-
ten informed consent had been obtained from all participants. 
Please see the supplementary note of Rusert et al. (2016) for fur-
ther details on the cohorts.
Subcohorts
Our study cohort comprises a large proportion of individuals 
with highly similar background (white ethnicity and subtype 
B infection) and a second, smaller proportion with differential 
background (differential ethnicity, non-B infection; Fig.  1 and 
Table S2). Comparing our findings in the white/B subcohort with 
the full cohort provides powerful means to substantiate our con-
clusions as we see the same effects in both settings. As preferen-
tial recognition by plasma from different subtypes is unavoidable 
when analyzing binding responses to antigens of different sub-
types, concordant data in both the white/B subcohort and the full 
cohort is particularly useful to exclude potential confounders.
In addition, we investigated subgroups of the white/B subco-
hort in Fig. 6 (see details of these subgroups in Fig. 5, A–C, and 
Table S2). To enable an unbiased evaluation, we restricted the 
analysis in Fig. 6 to the white/B subcohort and therein to individ-
uals with chronic HIV-1 infection (3–10 yr untreated infection) 
to ensure comparable infection length in neutralizers and non-
neutralizers. This was necessary as infection length is a driver 
of antibody development and bnAb activity in particular (Rusert 
Figure 10. Two-dimensional representation of all plasma samples based on binding antibody responses. Two-dimensional t-SNE map (Barnes-Hut-SNE 
approximation with 1,000 iterations) of all plasma samples (n = 4,281) based on the relative binding activities to BG505 trimer (IgG1 and IgG2) and MPER-2/4 
(IgG1 and IgG3). (A) Points in each subplot are colored by the strength of response to one of the four relative binding activities (red color denotes high binding 
activity, and blue denotes low binding activity). (B–D) The t-SNE map from A is stratified by neutralization capacity, cross (n = 684; C), broad (n = 178; D), and 
elite (n = 58; E) neutralization. (E) The t-SNE map from A is stratified by neutralization capacity of plasma (all, cross, broad, or elite neutralization). Plasma with 
high relative binding (>0.667) for either IgG1 (blue) or IgG3 (red) MPER-2/4 or both (green) is colored. (F) The t-SNE map from A is stratified by neutralization 
capacity of plasma (broad or elite neutralization). Plasma with predicted MPER specificity (n = 19) is colored.
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et al., 2016). We previously demonstrated comparable bnAb fre-
quency in individuals infected for >3 yr, but lower frequency in 
individuals infected for <3 yr (Rusert et al., 2016). We therefore 
excluded the latter individuals in the analysis in Fig. 6 to elimi-
nate influences of infection length.
A further subgroup analysis of the white/B subcohort investi-
gated early versus chronic HIV infection in Fig. 7. Data on the com-
position of these subgroups are shown in Fig. 5 C and Table S2.
Patient data
Both SHCS and ZPHI maintain a comprehensive, longitudinal, 
anonymous data collection of all participants, including exten-
sive clinical and demographic data. The following data were used 
in the current study: longitudinal viral load and CD4 measure-
ments, clinical history (antiretroviral drug history, infection 
length, and patient demographics), and pol nucleotide sequence 
data from genotypic antiretroviral drug resistance tests. The eth-
nicity (race) information is self-reported by the SHCS and ZPHI 
study participants at enrollment. Study nurses or study physi-
cians use a structured interview questionnaire and participants 
are asked whether they belong to one of the following races/eth-
nicities: white, black, Hispano-American, or Asian. These cat-
egories cover the major ethnicities in Switzerland. Health care 
access is guaranteed for all races/ethnicities living in Switzerland 
and the same is true for participation in the SHCS and the ZPHI. 
We used pol data to estimate the viral diversity for two reasons: 
(1) we had access to pol data, as they were available from drug 
resistance tests. Full Env diversity determination for 4,281 indi-
viduals was not feasible. (2) pol data will give an unbiased esti-
mate of diversity. Env diversity may be greater, but also has the 
chance to fluctuate more depending on whether the sampling 
time coincides with a dominant escape to the neutralization 
response or not. Please see the supplementary note of Rusert et 
al. (2016) for further details on how patient data were recorded. 
The following eight host, viral, and disease parameters were 
included in the analysis of the current study: viral load, CD4 
count, infection length, virus diversity, gender, transmission 
mode, ethnicity, and viral pol subtype. The distributions of the 
parameters across the 4,281 patients analyzed in the current 
study are summarized in Table S2.
HIV-1 antigens
We selected 13 HIV-1 antigens covering structural Gag proteins 
(p17 and p24) and various Env antigens from different HIV-1 sub-
types to establish HIV-binding antibody landscapes. Properties, 
sources, and details to production and purification of HIV-1 anti-
gens are listed in Table S1 in (Liechti et al., 2018). We thank D. 
Burton (The Scripps Research Institute, La Jolla, CA), J.P. Moore 
(Cornell University, Ithaca, NY), R. Sanders (Academic Medical 
Center, Amsterdam, Netherlands), P.D. Kwong (National Insti-
tutes of Health Vaccine Research Center, Bethesda, MD), and J. 
Robinson (University of Zurich, Zurich, Switzerland) for pro-
viding proteins, peptides, or expression plasmids for this study.
We compared plasma antibody activity to various Env proteins 
and peptides: open Env conformations (JR-FL gp120 monomer 
[JR-FL gp120; Subtype B], BG505 gp140 monomer [BG505 gp140; 
Subtype A], V3 loop peptides of strains JR-FL, MN, and BG505 
[V3 JR-FL, V3 MN, and V3 BG505]) with the closed, native-like 
trimer BG505 SOS IP.664 (BG505 trimer; Subtype A). To estimate 
CD4bs-directed responses, we probed plasma antibody activity to 
the V1-V3 loop truncated HxB2 derived core Env construct Resur-
faced Stabilized Core 3 (RSC3) containing a preserved CD4bs and 
the RSC3Δ371Ι construct (RSC3Δ), which is not bound by most 
CD4bs antibodies (Wu et al., 2010). Within gp41, two MPER pep-
tides, MPER-2/4 (encompassing the 2F5 and 4E10 bnAb epitopes) 
and MPER-2/4/10 (encompassing 2F5, 4E10, and 10E8 bnAb epi-
topes), and a truncated gp41 trimer construct lacking the MPER 
domain (gp41ΔMPER) were probed. All peptides were chemically 
biotinylated as indicated in Table S2. With the exception of p24 
and gp41ΔMPER, all proteins were expressed with an avi-tag and 
enzymatically monobiotinylated (Avidity, LLC).
Profiling of the Swiss 4.5K cohort for HIV-1–binding antibodies 
using a customized multivariate multiplex bead assay
To measure the plasma IgG1-, IgG2-, and IgG3-binding antibody 
activity to the 13 selected Gag and Env HIV-1 antigens in the 4,281 
included individuals, we used a high-throughput bead-based 
multiplexed immunoassay using the Luminex technology. We 
thank J. van Gils, T. Zborowski, and the Luminex Corporation 
(Hertogenbosch, Netherlands) for providing the FlexMap 3D 
instrument. The antigenicity of all 13 tested HIV-1 antigens in 
this Luminex-based binding assay has been previously estab-
lished (Liechti et al., 2018). Importantly, the antigenicity of the 
BG505 trimer in this assay is identical to what was described pre-
viously with the BG505 trimer preferentially binding bnAbs and 
only allowing low level of non-/low-neutralizing V3 loop anti-
body binding compared with open Env versions (Yasmeen et al., 
2014; Liechti et al., 2018).
Carboxylated MagPlex beads (Luminex) were covalently 
directly coupled with antigens (p24 and gp41ΔMPER) or coupled 
with Neutravidin (Thermo Fisher Scientific), followed by load-
ing with biotinylated antigens (all others). For each antigen/ana-
lyte, a unique bead region was chosen to allow multiplexing of 
all 13 antigens. Coupling was done using a coupling kit (BioRad) 
according to the manufacturer’s instructions. In brief, 12.5 Mio 
beads were sonicated and thoroughly washed with the activa-
tion buffer provided by the coupling kit. The carboxyl groups on 
the beads were activated in 100 µl activation buffer containing 
sulfo-N-hydroxysulfosuccinimide (S-NHS; Thermo Fisher Sci-
entific) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC; Thermo Fisher Scientific) at a concentra-
tion of 5 mg/ml. After 20 min of activation at room temperature, 
beads were thoroughly washed with activation buffer, and beads 
were coupled in 500 µl PBS containing the respective proteins 
(50 µg gp41ΔMPER, 62.5 µg p24, or 62.5 µg Neutravidin) for 
2 h at room temperature. Beads were then washed thoroughly, 
blocked with PBS-BSA 1% for 30 min at room temperature, and, 
after extensive washing, stored in PBS-BSA 1% at a bead concen-
tration of 20,000 beads/µl at 4°C.
Biotinylated proteins were coated on Neutravidin-coupled 
beads and subsequently blocked with biotin. Proteins and bio-
tin were diluted in PBS at a concentration of 320 nM and coat-
ing and blocking were performed for 1 h at room temperature. 
Beads were extensively washed with PBS-BSA 1% and stored 
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at a concentration of 10,000 beads/µl at 4°C and were used 
for up to 2 wk.
We established binding antibody profiles at fixed plasma dilu-
tions of 1:100 (for all antigens and IgG subclasses) and 1:6,500 
(IgG1 responses of highly reactive antigens p17, p24, gp120 JR-FL, 
and gp41ΔMPER).
The different bead regions carrying the different antigens 
were mixed at each experiment and incubated with patient 
plasma at dilution 1:100 and 1:6,500 in PBS-BSA 1% overnight at 
4°C to allow plasma IgG binding to antigen-coated beads. Beads 
were washed with PBS-BSA 1%, distributed on 3 separate wells of 
96-well plate, and IgG responses were detected with phycoeryth-
rin-labeled secondary antibodies specific to isotypes IgG1, IgG2, 
and IgG3 diluted in PBS-BSA 1% at a concentration of 1 µg/ml 
(Southern Biotech). After extensive washing with PBS-BSA 1%, 
beads were analyzed with the FlexMap 3D instrument (Luminex). 
A minimum of 50 beads per antigen and plasma were acquired 
to guarantee accurate mean fluorescence intensity (MFI) val-
ues. Quality control and validation procedures for the FlexMap 
3D instrument were done on each day of experiment according 
to manufacturer’s instructions, and monoclonal HIV-1–specific 
antibodies (PG09, 2F5, 19b, 2G12, 447-52D, and HIV IG) were ana-
lyzed with each experiment as assay quality control. IgG1 activity 
to p17, p24, gp120 JR-FL, and gp41ΔMPER is generally high and 
was thus analyzed at a 1:6,500 plasma dilution; all other antigens 
and IgG subclass responses were measured at a 1:100 plasma dilu-
tion to retrieve readout values in the dynamic range of the assay.
The binding reactivity of the 4,281 plasma samples was 
screened on 15 different days over a 2-mo period. Antibody reac-
tivity to certain antigens showed only modest differences across 
the patient population (Fig. 1 C). In these cases, even small dif-
ferences in measured binding intensities, caused, for instance, 
by day-to-day assay variability could potentially influence the 
analysis. We showed previously that influences of day-to-day 
variability can be prevented by transforming measured MFI val-
ues to per-day relative binding activities (Liechti et al., 2018). To 
retrieve the relative binding data, we considered for each antigen 
and IgG subclass combination the ordinal ranking of a plasma 
sample relative to all samples tested on the same day (ranging 
between 122 to 354 samples tested per day) and assigned a score 
of 0 to the lowest and 1 to the highest ranked sample and a lin-
early changing score to all other samples per day as described 
previously (Liechti et al., 2018; Table S1). This transformation 
was valid thanks to the high number of samples tested per day 
and allowed us to rule out a significant influence of single outli-
ers. Importantly, the established intra- and interassay variability 
of the binding assay further allowed us to rely on single measure-
ments of each plasma sample (Liechti et al., 2018). All postmea-
surement analyses performed on the HIV-1 IgG–binding dataset 
except for the analysis reported in Fig. 9 used the relative binding 
data (Table S1).
Dissection of host, viral, and disease parameters that 
influence IgG binding
We used univariable and multivariable linear regression models 
to measure the influence of eight host, viral, and disease param-
eters on plasma IgG binding to the various HIV-1 antigens (using 
Python 2.7 and its library statsmodels0.8.0-3). Log10 viral load 
and CD4 level (both measured at time of sampling), viral pol 
diversity (Kouyos et al., 2011), and infection length were included 
as continuous variables. The remaining four factors were used 
as categorical variables and analyzed in relation to the reference 
category (sex: reference male; mode of transmission: reference 
men having sex with men [MSM]; ethnicity: reference white; 
HIV-1 subtype: reference subtype B). The multivariate analyses 
in Fig. 2 included all eight parameters. In the analyses in Fig. 3, 
the variables HIV-1 subtype and ethnicity were excluded, and 
only plasma samples of white individuals with subtype B infec-
tion (the white/B subcohort) were considered. In Fig. 4, the dif-
ference in plasma IgG binding between two IgG subclasses was 
compared for both the full cohort and the white/B subcohort. In 
this analysis, neutralization breadth is added as an additional cat-
egorical covariable. Patients were defined to have neutralization 
breadth if their plasma reached cross, broad, or elite neutraliza-
tion activity score as determined in Rusert et al. (2016).
Predictive power of HIV-1 binding activities on HIV-1 
neutralization breadth
Neutralization breadth scores for all tested plasma samples were 
available from the Swiss 4.5K Screen (Rusert et al., 2016) and are 
listed in Table S1. In brief, neutralization breadth scores were 
determined according to the neutralization of multiclade eight-vi-
rus panel using the Env pseudovirus luciferase reporter assay on 
TZM-bl cells (Rusert et al., 2016). Neutralization activity of plasma 
probed at a fixed dilution of 1:150 against a specific virus received 
a score of 0 when neutralization activity was <20%, a score of 1 
when neutralization activity ranged between ≥20% and <50%, a 
score of 2 for neutralization between ≥50% and <80%, and a score 
of 3 for neutralization ≥80% (Rusert et al., 2016). The sum of scores 
against all 8 viruses reflects the cumulative potency and breadth 
neutralization score we used for further analysis. The maximum 
cumulative neutralization score a plasma could reach was 24. 
Scores of ≥15 were classified as elite neutralization, scores of 10–14 
as broad neutralization, scores of 5–9 as cross neutralization, and 
scores <5 as no or weak neutralization activity.
To quantify the predictive power of a set of binding activi-
ties on HIV-1 neutralization activity, the set of all 4,281 plasma 
samples was partitioned into a training set (80%) and a test set 
(20%). Based on the training set, a univariable (if only one bind-
ing activity was considered as explanatory variable, as in Fig. 8, 
B and C) or multivariable (if multiple binding activities were 
considered as explanatory variables, as in Fig. 8, D–G) logistic 
regression model with breadth of neutralization response as the 
binary outcome variable was learned. We then used the learned 
model to rank the plasma samples of the test set and quantified 
the quality of the resulting ranking using the AUC of the ROC. In 
this analysis, a random predictor yields an AUC = 0.5, and a per-
fect predictor yields AUC = 1. We conducted three separate analy-
ses for different choices of positives: at least cross neutralization 
(score > 4), at least broad neutralization (score > 9), and elite 
neutralization (score > 14). In each set-up, all remaining plasma 
samples were set as negatives. The reported mean AUC values are 
the result of 100 repetitions, each with fivefold cross-validation 
(i.e., partitioning of the set of all plasma samples into five equally 
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sized sets and using each set four times as part of the training set 
and once as the test set). Uncertainties in the AUC values are not 
depicted graphically in Fig. 8 because the confidence intervals 
were negligibly small, limiting possibilities for visualization (see 
minimum and maximum AUC values in Table S4).
Profiling of the 105 broadest neutralizing plasma samples for 
HIV-1–binding antibody signatures
To allow a precise comparison of plasma IgG binding reactivity of 
the 105 broadest neutralizing plasma samples that we previously 
identified in the Swiss 4.5K Screen (Rusert et al., 2016), we sub-
jected the 105 bnAb plasma to a separate assessment of HIV-1–
binding activity in the multivariate multiplex bead assay using 
a wider range of plasma dilutions for IgG1 (1:400, 1:3,200, and 
1:25,600) and a 1:400 plasma dilution for IgG2 and IgG3 to opti-
mize measurements within the dynamic range of the respective 
responses. All samples were processed on a single day and mea-
sured on a Luminex FlexMap 3D reader. For each specific HIV-1 
antigen, we considered an IgG1 dilution in the dynamic range of 
the assay. RSC3, RSC3Δ, MPER-2/4, and MPER-2/4/10 were mea-
sured in a 1:400 dilution, p24, and V3 MN in a 1:3,200 dilution, 
and p17, gp120 JR-FL, BG505 gp140, BG505 trimer, V3 JR-FL, V3 
BG505, and gp41ΔMPER in a 1:25,600 dilution. The entire anal-
ysis was conducted in a single run excluding the possibility of 
assay-to-assay variations, as previously described (Liechti et al., 
2018), and thus effective MFIs (Table S1), instead of relative bind-
ing data, could be used for the analysis reported in Fig. 9.
Predictive power of HIV-1–binding activities on bnAb specificity
To assess if specific HIV-1–binding antibody profiles predict bnAb 
specificity, we conducted multivariable linear regression analy-
ses using detailed neutralization fingerprint data available for 
the top 105 bnAb plasmas and the HIV-1–binding antibody data 
available for the same patients (using Python 2.7 and its library 
statsmodels0.8.0-3). Details and results of the fingerprinting 
analysis of the 105 bnAb plasmas have been described (Rusert 
et al., 2016). In brief, half-maximum neutralization titer (NT50) 
of the 105 plasmas and 50% inhibitory concentrations (IC50) of 
bnAbs with known epitope specificities were determined against 
a 40 multiclade virus panel in the TZM-bl assay. bnAb specific-
ity in plasma was then determined using a maximal Spearman–
based prediction method (Rusert et al., 2016); that is, a plasma 
was assigned to the bnAb with the most similar neutralization 
fingerprint, where similarity was measured using the Spearman 
correlation of the IC50 values of the monoclonal antibodies and 
the inverse NT50 values of the plasmas. The retrieved Spearman 
correlation can be used as a proxy for the plasma bnAb specific-
ity. Building on this data, we conducted in the current study mul-
tivariable linear regressions on the 105 bnAb plasmas with the 
maximal Spearman correlation of the neutralization fingerprint 
to a certain bnAb cluster (i.e., the plasma bnAb specificity) as the 
outcome variable and the binding activity to a certain antigen as 
the first explanatory variable (associations shown in Fig. 9 A). To 
avoid potential confounding effects (preferential reactivity with 
antigens and viruses of the same subtype), the viral pol subtype 
(B vs. non-B) was included as a second explanatory variable 
(associations shown in Fig. 9 B).
Blinding
Personnel who conducted the HIV-1–binding antibody analysis 
reported here and the previously reported neutralization screen 
(Rusert et al., 2016) had no information on patient demographics 
and neutralization activity at the time of analysis.
Statistical analysis
Statistical analyses were performed in Python 2.7 using the pack-
ages scipy.stats, statsmodels, and tsne as well as in R3.4.1 using its 
libraries circlize, car, and betareg. 
Using the collected binding data, we used multivariable lin-
ear regression models to assess how individual factors influence 
HIV-1 IgG responses (Figs. 2 and 3), as well as how they influence 
the difference in responses between two IgG subclasses (Fig. 4). 
Although only multivariable analyses have the power to disen-
tangle confounded effects, results from univariable analysis are 
additionally provided for each analysis, as divergent results in 
univariable and multivariable analyses best highlight which 
effects are most affected by other variables and can only be 
reliably assessed by multivariable tests. This provides import-
ant information, which needs to be considered in studies that, 
because of limited sample numbers, can only use univariable 
testing. We tested the appropriateness of the obtained linear 
models. As the relative binding activities are close to uniformly 
distributed in [0,1], outliers are not an issue. The ncv-test (R 
library car), which tests for heteroscedasticity, revealed 26 
out of 156 investigated models with P < 0.05; only two models 
showed significant heteroscedasticity after correcting for mul-
tiple testing. Given the large number of observations and the 
moderate p-values, heteroscedasticity is unlikely to have affected 
our results. Lastly, as a sensitivity analysis to Figs. 2 and 3, we 
investigated additional, more complicated β regression models 
(using a linear transformation of the response variables from 
[0,1] into (0,1); Smithson and Verkuilen, 2006) that take the dis-
tribution of the relative binding activities into account. These 
models revealed very similar associations as reported in Figs. 2 
and 3 (not depicted). We thus opted to report the results from 
the more frequently used and more easily interpretable linear 
regression analyses.
In Figs. 6 and 7, Spearman correlations were calculated for 
each pair of relative binding activities (respective parts A and 
B) and compared between the two subpopulations under inves-
tigation (respective parts C and D). To test for significant dif-
ferences in pairwise Spearman correlations (part C), the two 
subpopulations were randomly reshuffled 10,000 times, keep-
ing only the respective sizes fixed. Each time, the differences in 
Spearman correlations between the reshuffled subpopulations 
were recorded and finally compared with the observed differ-
ences found in the true subpopulations. If there was no true dif-
ference in correlation between the two subpopulations, ∼5,000 
of the reshuffled correlations were expected to be higher than 
the observed correlation and 5,000 lower. We thus calculated the 
p-value of an observed correlation as
  p shuffle =  
min ( m, 10, 000 − m )   _______________5, 000 , 
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where m is the number of reshuffled correlations higher than 
the observed correlation. To test whether two antibody response 
landscapes exhibit significantly different “between IgG subclass” 
Spearman correlations, we compared correlations between same 
antigens (part D) using the paired Wilcoxon test. The dimension-
ality reduction method t-SNE was used to display the plasma 
samples in two dimensions, taking into account their relative 
IgG1 BG505 trimer, IgG2 BG505 trimer, IgG1 MPER-2/4, and 
IgG3 MPER-2/4 binding activities (Fig.  10). As a result of the 
large cohort size, we used the well-established Barnes-Hut-SNE 
approximation (with 1,000 iterations and parameters theta = 0.5 
and perplexity = 200) instead of the exact t-SNE method (van 
der Maaten, 2013).
Multiple testing
All reported statistical analyses are of explorative, descriptive 
nature. We therefore opted, by default, not to formally adjust for 
multiple testing because false positives are less of a problem in 
explorative studies than false negatives. In addition, owing to the 
large size of our cohort, almost all the associations we focus on 
exhibit a very low p-value, much lower than a Bonferroni cor-
rected p-value (pBonferroni = 0.05/3 IgG isotypes/13 antigens/8–11 
predictors > 10−4) as can be seen in Figs. 2 and 3. Levels of sig-
nificance for Bonferroni-corrected p-values are shown in Figs. 2 
and 3 and allow assessment of multiple testing corrected values.
In Figs. 6 and 7, we used a Benjamini-Hochberg correction 
with a false discovery rate of 10% to correct for multiple test-
ing. The analysis reported in Fig. 9 was performed solely to test 
the association of bnAb specificities and binding activities for 
two bnAb types, CD4bs and MPER, and specific antigens (RSC3/
RSC3Δ and MPER peptides, respectively). We reported the results 
for the additional antigens and bnAb specificities only for com-
pleteness, but did not draw any conclusions because the out-
come cannot be interpreted appropriately without having bnAb 
type-specific antigens.
Online supplemental material
Table S1 contains all raw data (patient characteristics, relative 
binding activities, the effective measured binding responses 
[MFIs], and bnAb specificities for the 105 individuals with high-
est bnAb activity). Table S2 shows the characteristics of the 
various patient subpopulations analyzed in this study. Table S3 
contains the detailed regression results of the analyses shown 
in Figs. 2 and 3. Table S4 contains the mean AUC values for uni-
variable and multivariable prediction models of neutralization 
breadth shown in Fig. 8. Table S5 contains the detailed regression 
results of the analyses shown in Fig. 9.
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